INTERVIEW: Celgene's head dealmaker strikes a fair balance
This article was originally published in Scrip
Celgene is known among biotechnology firms for being a disciplined buyer and an ideal collaborator – a reputation in which the company's head dealmaker George Golumbeski takes a lot of pride.
You may also be interested in...
Private Company Edition: Celgene's former top deal-maker George Golumbeski is now a life science business consultant and venture partner at ARCH. Also, a VC investment surge portends another big year for biopharma, including $85m for Ansun and $66m for FogPharma.
Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.
Emerging Company Profile: Former Sanofi-Genzyme exec David Meeker signed on to lead the startup, which is using a CRISPR-based drug discovery platform to develop specifically targeted therapies, with an initial focus on oncology and immunology, after leaving big pharma.